- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Detecting PCa Recurrence in African Americans: Can 18F-Flotufolastat Have an Impact?
In a recent interview, Soroush Rais-Bahrami, M.D., discussed key findings from a post-hoc subgroup analysis of the SPOTLIGHT trial that examined the use of the PET imaging agent 18F-flotufolastat (Posluma) in African American men.
For African Americans with suspected prostate cancer (PCa) recurrence, the PET imaging agent 18F-flotufolastat (Posluma) provided a 93 percent patient-level detection rate (DR) that was six percent higher than that reported for other patients in the recent SPOTLIGHT trial.
Researchers also noted that 18F-flotufolastat had a 67 percent DR for African American patients with a prostate-specific antigen (PSA) level < 0.5 ng/mL and a 100 percent DR for those with a PSA level > 10 ng/mL in this patient population, according to the post-hoc analysis of the SPOTLIGHT trial that was recently published in Advances in Radiation Oncology.
In a recent interview, Soroush Rais-Bahrami, M.D., the lead author of the study, noted some small differences in regional detection rates between African Americans and other patients but said the findings were largely similar otherwise for the use of Posluma (Blue Earth Diagnostics) in diagnosing PCa recurrence.
“The findings holding true and being validated in large part both with imaging and histopathologic confirmation really make this new FDA-approved PSMA PET imaging agent valid in all populations of men, specifically African Americans as well as non-African American men included in the study,” maintained Dr. Rais-Bahrami, a professor in the Departments of Urology and Radiology at the University of Alabama School of Medicine in Birmingham, Ala.
Dr. Rais-Bahrami also noted that African American men comprised 17 percent of the SPOTLIGHT study cohort, nearly double the rate of African American participation reported in oncology clinical trials from 2010 to 2021.
“This shows promise that clinical trials, specifically in the realm of cancer, can have a good diversity of enrollment in terms of subjects. One of the real elements of our focus in terms of performing clinical trials should be sure to encourage not only diversity of race … but also different areas regionally throughout the country and internationally as well as different sites of practice to really reach patients with different points of access, socioeconomic status, race, ethnicity and cultural factors that may play a large role in their overall medical and specifically, in this case, cancer care,” emphasized Dr. Rais-Bahrami.
(Editor’s note: For related content, see “Emerging Research at SNMMI Examines 18F-Flotufolastat in Managing Primary and Recurrent Prostate Cancer,” “Can Targeted PSMA PET/CT Guided Radiotherapy Have an Impact for Oligometastatic Prostate Cancer?” and “Study: PSMA PET/CT More Advantageous than MRI for Locoregional Staging of Prostate Cancer.”)
For more insights from Dr. Rais-Bahrami, watch the video below.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
January 4th 2025In patients with high-risk, hormone sensitive prostate cancer who had no evidence of metastasis on conventional imaging, PSMA PET revealed polymetastatic disease in 24 percent of patients and M1 disease staging in 46 percent of patients.
Can MRI and Micro-Ultrasound Guidance Bolster Focal Laser Ablation Outcomes for Prostate Cancer?
January 3rd 2025For patients with localized prostate cancer and PI-RADS 3 or higher lesions, MRI-guided micro-ultrasound multifiber focal laser ablation had an 18 percent recurrence rate at one year, according to newly published research.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
